Third Pole Therapeutics announced that it has raised an additional $25 million in a financing round led by existing investors for continued development of its tankless inhaled nitric oxide (iNO) systems. The company also said that its eNOcare iNO platform is almost ready to launch and that clinical trials of its eNOfit wearable iNO device are expected to begin by the end of 2022 with a possible FDA submission by the end of 2023. In April 2020, Chiesi acquired global rights to develop and commercialize Third Pole iNO technology.
Third Pole CEO Bill Athenson commented, “We want to thank our existing investors who continue to support Third Pole’s mission to develop our novel technology into approved products for patients in need. We also welcome our new investors who have joined us in support of this important mission. We are now much closer to improving the lives of 1.2 million patients battling severe COPD and ILD (pulmonary fibrosis) and who struggle with each breath to perform the day-to-day activities that most people take for granted. Feedback on our novel device from physicians has been extremely positive. They tell us that our light-weight mobile device has the potential to reduce patients high flow supplemental oxygen dependence, improve their mobility by allowing treatment while traveling and at home, and reduce the risk of heart failure by lowering pulmonary hypertension. These benefits may allow patients to live higher quality lives, require less intensive hospital care and live longer.”
Read the Third Pole Therapeutics press release.
